Positive Bylvay data in severe itch and serum bile acid levels

French drugmaker Ipsen (Euronext: IPN) today announced the long-term efficacy and safety of patients treated with Bylvay (odevixibat) from two Phase III open-label extension studies.

The late-breaking abstract on PEDFIC 2 in progressive familial intrahepatic cholestasis (PFIC) and oral presentation ASSERT-EXT in Alagille syndrome (ALGS) were presented at the American Association for the Study of Liver Diseases (AASLD).

Ipsen acquired rights to Bylvay along with its around $1 billion buy of USA-based Albireolast year. Bylvay generated sales of 37 million euros ($39 million), up 66.0%, in the third quarter of this year.